Himadri Speciality Chemicals has set a target to scale the business of its wholly owned arm Birla Tyres to Rs 3,000 crore (Rs 30 bn) over the next few years. The plan follows the acquisition of Birla Tyres in 2023 under an insolvency resolution with Dalmia Bharat Refractories for Rs 347 crore (Rs 3.47 bn). The target reflects management's intention to tap premium and export markets and to capitalise on rising demand for electric vehicle tyres. The company said the strategy has shifted from restarting operations to scaling the business, with a focus on modernising infrastructure and moving production away from truck and bus tyres towards higher margin off the road tyres. Himadri's chairman and chief executive officer Anurag Choudhary described the turnaround as progressing steadily under the new approach. The firm is prioritising investments in plant upgrades and production realignment to favour off the road tyre lines. The growth blueprint emphasises premium products, exports and electric vehicle tyres, and envisages the introduction of nearly 400 additional SKUs across agriculture, commercial vehicle, truck and bus and emerging segments. The firm also plans to enter the passenger car radial market, targeting EV and SUV categories with a dedicated PCR manufacturing facility slated for commissioning in FY28. Exports of agriculture and off the road tyres are expected to remain an important component of the expansion strategy. The SKU expansion is intended to address both domestic replacement markets and export customers. Birla Tyres generated revenue of Rs 187 crore (Rs 1.87 bn) in FY26, and the tyre business is seen as part of Himadri Speciality Chemicals' broader diversification into advanced battery materials and speciality chemicals. Management indicated that premiumisation, export growth and the PCR project will be central to reaching the stated revenue objective in the medium term. The company will continue to modernise manufacturing and adjust product mix to capture demand in electric vehicles and higher value segments. Progress on the PCR facility and export traction will be key indicators of how quickly the company approaches its target.